Artificial Oocyte Activation
- Conditions
- InfertilityOvarian Insufficiency
- Interventions
- Other: women having had a second IVF cycle with AOA
- Registration Number
- NCT06290895
- Lead Sponsor
- Clinique Ovo
- Brief Summary
Studies reported that calcium signal deficiency or insufficiency during oocyte activation are related with embryo arrest and blastocyst quality. The utilization of Artificial Oocyte Activation (AOA) is safe and does not increase birth defects, cognition, language and motor skills. AOA is the first line of treatment in patients with globozoospermia (round headed spermatozoa). Poor responders in in-vitro fertilization (IVF) cycles represent a major challenge for fertility specialists and comprises about 10-15% of patients undergoing controlled ovarian hyperstimulation. The absence of synergy between the oocyte and sperm leads to a negative impact on oocyte activation. The European Society of Human and REproduction (ESHRE) recommends AOA in cases with failed fertilization/ low fertilization.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 54
- Patients with poor or no blastocyst development in their primary cycle
- Group 1 - second cycle using AOA following the poor blastocyst development cycle
- Group 2 - second cycle without AOA following the poor development cycle
- All cycles who do not have repeat cycles following the poor blastocyst development cycle
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description In-vitro fertilization (IVF) cycle using artificial oocyte activation (AOA) women having had a second IVF cycle with AOA -
- Primary Outcome Measures
Name Time Method Blastocyst rate 5 days after oocyte fertilization Likelihood of an oocyte fertilized to blastocyst stage
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Clinique Ovo
🇨🇦Montréal, Quebec, Canada